Lexington Medical: Medtronic Antitrust Lawsuit Over Surgical Staplers

• Lexington Medical has filed a federal antitrust lawsuit against Medtronic, alleging monopolistic practices in the surgical stapler market.
• The suit claims Medtronic maintains over 90% market share through exclusionary bundling, long-term contracts, and by preventing competitor product trials.
• Lexington Medical asserts its AEON Endoscopic Stapling System is clinically superior but cannot compete due to Medtronic's alleged anti-competitive conduct.
• The lawsuit, filed under the Sherman Act and Massachusetts antitrust law, seeks unspecified damages and an injunction against Medtronic's exclusionary agreements.
• This action follows a previous antitrust case where Medtronic paid $382 million for an unlawful monopoly related to blood-vessel sealing devices.

Lexington Medical contends that Medtronic's alleged tactics effectively lock hospitals into its product ecosystem for extended periods, leading to increased costs, limited choices, and stifled innovation within the medical device sector.

A federal antitrust lawsuit has been initiated against Medtronic, a global medical device manufacturer, by Massachusetts-based Lexington Medical. The 63-page claim, filed in federal court in Boston, accuses Medtronic of engaging in monopolistic practices designed to unlawfully exclude competitors from the market for laparoscopic universal handle staplers. These specialized instruments are crucial for cutting and sealing tissue during minimally invasive surgical procedures.

Lexington Medical, which specializes in these staplers, asserts that its AEON Endoscopic Stapling System outperforms Medtronic's comparable offerings. Despite this claimed clinical superiority, Lexington argues that Medtronic's restrictive agreements with client hospitals have effectively prevented its product from gaining traction. Medtronic, with operational headquarters in Minneapolis, Minnesota, and legal and executive headquarters in Ireland, is alleged to control more than 90% of the laparoscopic stapler market, a dominance Lexington Medical contends is maintained through anti-competitive conduct rather than product merit.

The lawsuit details several strategies Medtronic allegedly employs to preserve its market stronghold. These include actively discouraging hospitals from conducting trials of rival products, implementing exclusionary bundling arrangements, and compelling clients into long-term contracts. Lexington Medical claims that these practices result in hospitals being bound to Medtronic's product portfolio for years, which in turn leads to higher prices, reduced choices, and a dampening of innovation across the industry.

Internal documents cited in the lawsuit purportedly reveal Medtronic's directives to its sales force to "communicate violation" if a hospital began evaluating competitor products. Another document reportedly articulated a goal to "eliminate the competition from getting a window that would allow for a trial." Lexington further alleges that Medtronic's bundling strategy is designed to make it "impossible" for competitors to secure deals, as bundled discounts are not simple volume incentives but rather portfolio-wide mechanisms that protect Medtronic's stapling market share by linking purchases across multiple product categories, including staplers, monopolar devices, advanced bipolar devices, and other surgical products. Statements from Medtronic executives, such as CEO Geoff Martha in 2025 referring to "very tight contracts that have been tested over time," and a regional vice-president boasting of customers being "locked down for years to come," are also referenced as evidence of these long-term, restrictive agreements.

Lexington Medical's complaint asserts violations of the Sherman Act and breaches of Massachusetts antitrust law. The company is seeking unspecified damages and a court order to prohibit Medtronic from entering into what it describes as exclusionary and predatory agreements. This legal action is not Medtronic's first encounter with antitrust scrutiny; the alleged scheme, according to Lexington, came to light through a separate federal antitrust case brought by Applied Medical Resources Corp. In that prior case, Medtronic was compelled to pay $382 million in damages for an unlawful monopoly related to blood-vessel sealing surgical devices.

Lexington Medical contends that its AEON stapler, which one hospital trial rated as "clinically superior" to Medtronic's in 89% of cases, would succeed on its merits if not for Medtronic's alleged anticompetitive conduct. Representatives for Medtronic have not yet responded to requests for comment regarding the new lawsuit.

This Medtronic antitrust lawsuit concerning surgical staplers highlights critical issues for compliance officers and legal counsel within the medical device industry. The allegations underscore the potential legal risks associated with aggressive sales, contracting, and bundling practices, especially those involving long-term agreements and efforts to impede competitor product trials. Lexington Medical contends that Medtronic's alleged tactics effectively lock hospitals into its product ecosystem for extended periods, leading to increased costs, limited choices, and stifled innovation within the medical device sector.

The lawsuit serves as a significant indicator of potential enforcement trends and the heightened scrutiny faced by dominant players in the medical device market. Companies must carefully review their strategies to ensure adherence to antitrust laws and mitigate exposure to similar monopolistic claims. The case emphasizes the importance of fostering fair competition and allowing medical innovation, such as Lexington Medical's AEON Endoscopic Stapling System, to compete on its own merits without artificial barriers.

Compliance officers and legal counsel in the medical device sector should review their sales, contracting, and bundling practices, particularly concerning long-term agreements and competitor trials, to ensure adherence to antitrust laws and mitigate exposure to similar monopolistic claims. This lawsuit highlights potential enforcement trends and risks associated with maintaining market dominance through exclusionary conduct.

Source: Original reporting via Court News Service